AssetMark Inc’s ARK Genomic Revolution ETF ARKG Stock Holding History

AssetMark Inc’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42	Hold	1	–	–	﹤0.01%	3506
2026 Q1	$26	Hold	1	–	–	﹤0.01%	3418
2025 Q4	$29	Buy	+1	New	+$30	﹤0.01%	3351
2022 Q2	–	Sell	-57	Closed	-$3K	–	1471
2022 Q1	$3K	Buy	+57	New	+$2.72K	﹤0.01%	1341
2021 Q4	–	Sell	-13,397	Closed	-$1M	–	1505
2021 Q3	$1M	Sell	13,397 -5,414	-29%	-$454K	﹤0.01%	390
2021 Q2	$1.74M	Buy	18,811 +3,635	+24%	+$309K	0.01%	334
2021 Q1	$1.35M	Buy	15,176 +1,617	+12%	+$160K	0.01%	339
2020 Q4	$1.26M	Buy	+13,559	New	+$1.08M	0.01%	335

Other funds holding ARKG

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $1.02B AUM 31.16% 1-Year Est. Return

MFPI

Midwest Financial Partners Investments St. Cloud, Minnesota $241M AUM

CIC

Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

CFIM

Client First Investment Management West Bend, Wisconsin $237M AUM 90.26% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

MWM

Moran Wealth Management Naples, Florida $3.67B AUM 36.71% 1-Year Est. Return

AssetMark Inc's ARKG Position: Q2 2026 in Review

AssetMark Inc held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2026 at 1 share worth $42. The position accounts for ﹤0.01% of the portfolio, ranked #3506.

AssetMark Inc first reported a position in ARKG in Q4 2020 and has held it in 8 quarters since. The position peaked at $1.74M in Q2 2021. 136 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

AssetMark Inc held 1 share of ARK Genomic Revolution ETF worth $42 as of Q2 2026.
AssetMark Inc left its ARK Genomic Revolution ETF share count unchanged in Q2 2026.
ARK Genomic Revolution ETF made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3506 holding.
AssetMark Inc first reported a position in ARK Genomic Revolution ETF in Q4 2020 and has held it in 8 quarters since.
AssetMark Inc's ARK Genomic Revolution ETF position peaked at $1.74M in Q2 2021.
136 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.